A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
Zhang Y, Elsik M, Edgley AJ, Cox AJ, Kompa AR, Wang B, Tan CY, Khong FL, Stapleton DI, Zammit S, Williams SJ, Gilbert RE, Krum H, Kelly DJ.
Zhang Y, et al. Among authors: krum h.
Int J Cardiol. 2013 Sep 30;168(2):1174-85. doi: 10.1016/j.ijcard.2012.11.067. Epub 2012 Dec 6.
Int J Cardiol. 2013.
PMID: 23219315